Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/OnKure Therapeutics, Inc./ 10-Q

Quarterly Report · 10-Q

OnKure Therapeutics, Inc.

OKURNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 4, 2026Accepted Aug 4, 2026, 4:05 PM EDTCIK 1637715Accession 0001193125-26-332773
View company →Permanent SEC source ↗
Share

Company context

OnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of vascular anomalies and cancers that are underserved by available therapies. Using a structure and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of vascular anomalies and cancer. OnKure aims to become a leader in targeting PI3Kα and has multiple programs designed to enable best-in-class targeting of this important molecular target.

Current securities

OKURNASDAQ · EQUITY · Current
Historical securities (1)
RPHMOTC · EQUITY · Historical · closed Oct 4, 2024

Recent company filings

  1. 4 filingSep 23, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 13, 2026
  3. 4 filingAug 11, 2026
  4. 4 filingAug 11, 2026
  5. 424B5 filingAug 4, 2026

Registered securities in this filing

ONKURE THERAPEUTICS, INC. · 10-Q · Filed 2026-08-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
OKUR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_6661b0f8-348f-47d8-9915-1582460d91db

Dimensions: Not supplied

Accession 000119312526332773 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.